Document is current
Any future updates will be listed below
-
Authors
Gallagher, Rigina L.
Koscik, Rebecca Langhough
Moody, Jason F.
Vogt, Nicholas M.
Adluru, Nagesh
Kecskemeti, Steven R.
Van Hulle, Carol A.
Chin, Nathaniel A.
Asthana, Sanjay
Kollmorgen, Gwendlyn
Suridjan, Ivonne
Carlsson, Cynthia M.
Johnson, Sterling C.
Dean, Douglas C. III
Zetterberg, Henrik
Blennow, Kaj
Alexander, Andrew L.
Bendlin, Barbara B. http://orcid.org/0000-0002-0580-9875
-
Funding
Funding for this research was provided by:
National Institute on Aging (P30AG062715, F30AG059346, R01AG037639, R01AG027161, R01AG059312, R01AG054059)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090256)
Swedish Research Council (2018-02532, 2017-00915)
H2020 European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C)
Swedish Alzheimer Foundation (AF-742881)
Hjärnfonden (FO2017-0243, FO2019-0228)
HORIZON EUROPE European Research Council (860197)
National Institute of General Medical Sciences (T32 GM008692)
Rath Foundation Academic Scholarship
- License Information
-
More Information
Article History
Received: 3 December 2021
Accepted: 27 July 2023
First Online: 17 October 2023
Declarations
:
: This study was approved by the Health Sciences Institutional Review Board at the University of Wisconsin-Madison and all participants provided informed consent to participate.
: Not applicable (no one’s personal data was used in the making of this manuscript).
: Roche Diagnostics International Ltd (Rotkreuz, Switzerland) provided CSF testing equipment and analysis for Drs. Bendlin and Johnson. COBAS, COBAS E, and ELECSYS are trademarks of Roche. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders. It is used for research purposes only and is not approved for clinical use. Dr. Zetterberg has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, and JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. GK is a full-time employee of Roche Diagnostics GmbH (Penzberg, Germany). IS is a full-time employee and shareholder of Roche Diagnostics International Ltd (Rotkreuz, Switzerland).
